INTERVENTION 1:	Intervention	0
Bi-Weekly Schedule	Intervention	1
Pemetrexed: 500 mg/m2, intravenous (IV), every 14 days, until disease progression.	Intervention	2
pemetrexed	CHEBI:63616	0-10
disease	DOID:4,OGMS:0000031	62-69
Gemcitabine: 1500 mg/m2, intravenous (IV), every 14 days, until disease progression.	Intervention	3
gemcitabine	CHEBI:175901	0-11
disease	DOID:4,OGMS:0000031	64-71
INTERVENTION 2:	Intervention	4
21-Day Schedule	Intervention	5
Pemetrexed: 500 mg/m2, intravenous (IV), every 21 days, until disease progression.	Intervention	6
pemetrexed	CHEBI:63616	0-10
disease	DOID:4,OGMS:0000031	62-69
Gemcitabine: 1000 mg/m2, intravenous (IV) on Days 1 and 8 of a 21-day cycle, until disease progression.	Intervention	7
gemcitabine	CHEBI:175901	0-11
disease	DOID:4,OGMS:0000031	83-90
Inclusion Criteria:	Eligibility	0
Must have received prior chemotherapy with Taxol (paclitaxel) or Taxotere (docetaxel).	Eligibility	1
paclitaxel	CHEBI:45863	50-60
taxotere	CHEBI:46058	65-73
Less than 3 different chemotherapy treatments for metastatic disease.	Eligibility	2
disease	DOID:4,OGMS:0000031	61-68
Prior treatment with hormonal and/or radiation therapy.	Eligibility	3
Must have disease that can be measured.	Eligibility	4
disease	DOID:4,OGMS:0000031	10-17
Must be able to take care of self needs for example personal hygiene	Eligibility	5
Exclusion Criteria:	Eligibility	6
Must not be pregnant or breast-feeding.	Eligibility	7
Cancer that has spread to the brain.	Eligibility	8
cancer	DOID:162	0-6
brain	UBERON:0000955	30-35
Treatment with Gemcitabine or Pemetrexed	Eligibility	9
gemcitabine	CHEBI:175901	15-26
pemetrexed	CHEBI:63616	30-40
Unable to take folic acid or Vitamin B12	Eligibility	10
folic acid	CHEBI:27470	15-25
vitamin b12	CHEBI:176843	29-40
Treatment for another cancer within the last 5 years	Eligibility	11
cancer	DOID:162	22-28
Outcome Measurement:	Results	0
Overall Tumor Response	Results	1
Best overall (confirmed) response recorded from start of treatment until disease progression/recurrence, start of other anti-tumor therapy/intervention, or end of trial, whichever comes first. Response must be confirmed at least 6 weeks from previous scans. Best overall response assignment depends on both measurement and confirmation criteria.	Results	2
disease	DOID:4,OGMS:0000031	73-80
Time frame: Every 6 weeks from start of treatment until documented disease progression or for 6 months from last dose of study drug, whichever occurs first. After 6 months, clinical assessment every 12 weeks and radiologic test performed as clinically indicated	Results	3
time	PATO:0000165	0-4
disease	DOID:4,OGMS:0000031	67-74
drug	CHEBI:23888	127-131
Results 1:	Results	4
Arm/Group Title: Bi-Weekly Schedule	Results	5
Arm/Group Description: Pemetrexed: 500 mg/m2, intravenous (IV), every 14 days, until disease progression.	Results	6
pemetrexed	CHEBI:63616	23-33
disease	DOID:4,OGMS:0000031	85-92
Gemcitabine: 1500 mg/m2, intravenous (IV), every 14 days, until disease progression.	Results	7
gemcitabine	CHEBI:175901	0-11
disease	DOID:4,OGMS:0000031	64-71
Overall Number of Participants Analyzed: 52	Results	8
Measure Type: Number	Results	9
Unit of Measure: participants  Complete Response: 2	Results	10
Partial Response: 8	Results	11
Stable Disease: 26	Results	12
stable	HP:0031915	0-6
disease	DOID:4,OGMS:0000031	7-14
Progressive Disease: 14	Results	13
progressive	HP:0003676	0-11
disease	DOID:4,OGMS:0000031	12-19
Unknown: 2	Results	14
Results 2:	Results	15
Arm/Group Title: 21-Day Schedule	Results	16
Arm/Group Description: Pemetrexed: 500 mg/m2, intravenous (IV), every 21 days, until disease progression.	Results	17
pemetrexed	CHEBI:63616	23-33
disease	DOID:4,OGMS:0000031	85-92
Gemcitabine: 1000 mg/m2, intravenous (IV) on Days 1 and 8 of a 21-day cycle, until disease progression.	Results	18
gemcitabine	CHEBI:175901	0-11
disease	DOID:4,OGMS:0000031	83-90
Overall Number of Participants Analyzed: 21	Results	19
Measure Type: Number	Results	20
Unit of Measure: participants  Complete Response: 0	Results	21
Partial Response: 5	Results	22
Stable Disease: 10	Results	23
stable	HP:0031915	0-6
disease	DOID:4,OGMS:0000031	7-14
Progressive Disease: 6	Results	24
progressive	HP:0003676	0-11
disease	DOID:4,OGMS:0000031	12-19
Unknown: 0	Results	25
Adverse Events 1:	Adverse Events	0
Total: 17	Adverse Events	1
Anaemia 2/52 (3.85%)	Adverse Events	2
Febrile neutropenia 4/52 (7.69%)	Adverse Events	3
neutropenia	HP:0001875,DOID:1227	8-19
Pancytopenia 1/52 (1.92%)	Adverse Events	4
pancytopenia	HP:0001876,DOID:12450	0-12
Thrombocytopenia 0/52 (0.00%)	Adverse Events	5
thrombocytopenia	HP:0001873,DOID:1588	0-16
Abdominal pain 1/52 (1.92%)	Adverse Events	6
abdominal pain	HP:0002027	0-14
Constipation 1/52 (1.92%)	Adverse Events	7
constipation	HP:0002019,DOID:2089	0-12
Pyrexia 2/52 (3.85%)	Adverse Events	8
Hepatic failure 1/52 (1.92%)	Adverse Events	9
hepatic failure	HP:0001399	0-15
Hyperbilirubinaemia 1/52 (1.92%)	Adverse Events	10
Device related infection 1/52 (1.92%)	Adverse Events	11
Pneumonia 2/52 (3.85%)	Adverse Events	12
pneumonia	HP:0002090,DOID:552	0-9
Sepsis 1/52 (1.92%)	Adverse Events	13
sepsis	HP:0100806	0-6
Adverse Events 2:	Adverse Events	14
Total: 7	Adverse Events	15
Anaemia 0/21 (0.00%)	Adverse Events	16
Febrile neutropenia 1/21 (4.76%)	Adverse Events	17
neutropenia	HP:0001875,DOID:1227	8-19
Pancytopenia 0/21 (0.00%)	Adverse Events	18
pancytopenia	HP:0001876,DOID:12450	0-12
Thrombocytopenia 1/21 (4.76%)	Adverse Events	19
thrombocytopenia	HP:0001873,DOID:1588	0-16
Abdominal pain 0/21 (0.00%)	Adverse Events	20
abdominal pain	HP:0002027	0-14
Constipation 0/21 (0.00%)	Adverse Events	21
constipation	HP:0002019,DOID:2089	0-12
Pyrexia 1/21 (4.76%)	Adverse Events	22
Hepatic failure 0/21 (0.00%)	Adverse Events	23
hepatic failure	HP:0001399	0-15
Hyperbilirubinaemia 0/21 (0.00%)	Adverse Events	24
Device related infection 0/21 (0.00%)	Adverse Events	25
Pneumonia 0/21 (0.00%)	Adverse Events	26
pneumonia	HP:0002090,DOID:552	0-9
Sepsis 0/21 (0.00%)	Adverse Events	27
sepsis	HP:0100806	0-6
